The MSD Wellcome Trust Hilleman Laboratories is a joint venture between MSD Laboratories India LLC¹ and the Wellcome Trust.  MSD and the Wellcome Trust have pledged up to £90 million to facilitate establishment of the Laboratories over the first seven years. It will operate on a not-for-profit principle.

The Hilleman Laboratories will:

• Apply world-class vaccine development technologies and know-how to develop safe and effective vaccines
• Focus on novel vaccines in areas of high unmet medical need and existing vaccines that can be optimized to better meet the needs of developing countries
• Build partnerships that enable the widest possible access to these products

The Hilleman Laboratories aims to fill a key gap in vaccine development for developing countries by:

• Leveraging the Wellcome Trust’s strengths in biomedical research for health in developing countries
• Attracting a broad range of potential partners who can contribute to the goal of developing new or improved vaccines for developing countries
• Working towards a sustainable, long-term operating plan through a mixed economy of grant income and compensation from licensing revenues
• Encouraging innovation, transparency, and sustainability in order to achieve a long term impact

¹MSD Laboratories India LLC is a wholly-owned subsidiary of Merck & Co., Inc., Whitehouse Station, N.J. U.S.A.